A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis, PMID: 28787186
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma, PMID: 22743678
A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers, PMID: 29622380
Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma, PMID: 31315668
Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis, PMID: 29098604
Biological therapies for atopic dermatitis: An update, PMID: 30679974
Biological Therapies of Severe Asthma and Their Possible Effects on Airway Remodeling, PMID: 32625205
Biologics for Atopic Dermatitis, PMID: 33012322
Commonality of the IL-4/IL-13 pathway in atopic diseases, PMID: 28277826
Current and emerging biologics for the treatment of pediatric atopic dermatitis, PMID: 33078990
Docking analysis and the possibility of prediction efficacy for an anti-IL-13 biopharmaceutical treatment with tralokinumab and lebrikizumab for bronchial asthma, PMID: 29155876
Dose-Exposure-Response Relationship of the Investigational Anti-Interleukin-13 Monoclonal Antibody Tralokinumab in Patients With Severe, Uncontrolled Asthma, PMID: 28758192
Effect of monoclonal antibody drug therapy on mucosal biomarkers in airway disease: A systematic review, PMID: 32808380
Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial, PMID: 29793857
Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial, PMID: 26231288
Efficacy of biologics in atopic dermatitis, PMID: 32003247
Emerging Treatment Options in Atopic Dermatitis: Systemic Therapies, PMID: 29320765
Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma, PMID: 30649752
Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis: A phase 2b randomized study, PMID: 33333295
Innovation in Atopic Dermatitis: From Pathogenesis to Treatment, PMID: 31964499
Monoclonal antibodies in type 2 asthma: a systematic review and network meta-analysis, PMID: 31395084
New and Emerging Systemic Treatments for Atopic Dermatitis, PMID: 32519223
New and Emerging Therapies for Pediatric Atopic Dermatitis, PMID: 31364023
New Anti-Eosinophil Drugs for Asthma and COPD: Targeting the Trait!, PMID: 28583618
Novel Therapeutic Approaches and Targets for the Treatment of Atopic Dermatitis, PMID: 32525769
Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing, PMID: 26182954
Probiotics for treating eczema, PMID: 30480774
Relative efficacy of systemic treatments for atopic dermatitis, PMID: 30296535
Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2, PMID: 27956146
The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm, PMID: 28646393
The IL-13-OVOL1-FLG axis in atopic dermatitis, PMID: 31509236
The Safety and Efficacy of Anti-IL-13 Treatment with Tralokinumab (CAT-354) in Moderate to Severe Asthma: A Systematic Review and Meta-Analysis, PMID: 31152798
The tralokinumab story: Nothing is ever simple, PMID: 30659852
Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma, PMID: 30442714
Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis, PMID: 33744356
Tralokinumab for atopic dermatitis: a promising new therapy, PMID: 33347600
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2), PMID: 33000465
Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study, PMID: 25304132
Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials, PMID: 29792288
Tralokinumab for the Treatment of Atopic Dermatitis, PMID: 34155602
Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program, PMID: 29536781
Tralokinumab for uncontrolled asthma, PMID: 23268592
Tralokinumab in atopic dermatitis, PMID: 34390128
Tralokinumab pharmacokinetics and tolerability when administered by different subcutaneous injection methods and rates, PMID: 28590244
Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial, PMID: 33000503
Tralokinumab unsuccessful for management of severe, uncontrolled asthma, PMID: 29793858
Tralokinumab: First Approval, PMID: 34406631
Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb, PMID: 29906525
Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches, PMID: 30825336
What's New in Atopic Dermatitis, PMID: 30850043
For research use only. Not for human or drug use.
